Tachibana M.Takashima E.Torii M.Wu Y.Sattabongkot J.Tsuboi T.Mahidol University2025-06-292025-06-292025-01-01Expert Review of Vaccines Vol.24 No.1 (2025) , 509-52314760584https://repository.li.mahidol.ac.th/handle/123456789/110955Introduction: The World Health Organization has recommended two pre-erythrocytic malaria vaccines targeting Plasmodium falciparum. However, there is currently no vaccine available for Plasmodium vivax, the second leading cause of malaria. To eliminate malaria, transmission-blocking vaccines (TBVs) that can prevent infection of mosquitoes from humans would be helpful. Areas covered: This review summarizes the identification of targets, progress, and prospects in developing malaria TBVs. We searched PubMed for studies published up to 11 April 2025, using the terms [‘Pfs25’ OR ‘Pfs230’ OR ‘Pfs48/45’ OR ‘Pvs25’ OR ‘Pvs230’ OR ‘Pvs48/45’ OR ‘AnAPN1’] AND [‘malaria transmission-blocking vaccine’]. Expert opinion: After over 30 years of research and development, Pfs230 for P. falciparum and Pvs25 for P. vivax are the most advanced candidates for transmission-blocking vaccines.Pharmacology, Toxicology and PharmaceuticsBiochemistry, Genetics and Molecular BiologyImmunology and MicrobiologyReviewSCOPUS10.1080/14760584.2025.25177202-s2.0-1050087505401744839540488614